The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2016-09-30

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.4088/JCP.15032su1PMID 27732772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.

  2016cited by this paper
• Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

  2015cited by this paper
• Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia.

  2015cited by this paper
• Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia.

  2015cited by this paper
• Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.

  2015cited by this paper
• Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.

  2015cited by this paper
• Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance

  2015cited by this paper
• Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

  2015cited by this paper
• Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

  2015cited by this paper
• Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics

  2015cited by this paper
• A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.

  2015cited by this paper
• The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.

  2015cited by this paper
• Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.

  2015cited by this paper
• Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.

  2015cited by this paper
• Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

  2015cited by this paper
• Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management

  2014cited by this paper
• Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study

  2014cited by this paper
• Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.

  2014cited by this paper
• EPA-1549 - A Randomized, Active-controlled Rater-blinded 2-year Study of Paliperidone Palmitate Versus Investigators’ Choice of Oral Antipsychotic Monotherapy in Patients with Schizophrenia (prosipal)

  2014cited by this paper
• Hospitalization Resource Utilization and Costs Among Medicaid Insured Patients With Schizophrenia With Different Treatment Durations of Long-Acting Injectable Antipsychotic Therapy

  2014cited by this paper
• The Role of the Extended Health Care Team in Successful LAI Therapy: Education to Overcome Barriers

  2014cited by this paper
• Long-acting injectable antipsychotics: an underutilized treatment option.

  2014cited by this paper
• Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

  2014cited by this paper
• Clinical predictors of therapeutic response to antipsychotics in schizophrenia

  2014cited by this paper
• Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden

  2014cited by this paper
• Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

  2014cited by this paper
• A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections

  2014cited by this paper
• Quantifying clinical relevance.

  2014cited by this paper
• The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

  2014cited by this paper
• When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed

  2013cited by this paper
• Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia

  2013cited by this paper
• Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non‐adherent patients with schizophrenia

  2013cited by this paper
• Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.

  2013cited by this paper
• A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach

  2013cited by this paper
• Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

  2013cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

  2013cited by this paper
• New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia

  2013cited by this paper
• An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.

  2013cited by this paper
• Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.

  2013cited by this paper
• The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia

  2013cited by this paper
• Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.

  2013cited by this paper
• Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

  2012cited by this paper
• Defining "patient-centered medicine".

  2012cited by this paper
• A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan.

  2012cited by this paper
• Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable

  2012cited by this paper
• Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.

  2012cited by this paper
• Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

  2011cited by this paper
• Evaluation of health services use following the initiation of risperidone long‐acting therapy among schizophrenia patients in the veterans health administration

  2011cited by this paper
• Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

  2011cited by this paper
• Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

  2011cited by this paper
• A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

  2011cited by this paper
• Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.

  2011cited by this paper
• A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

  2011cited by this paper
• A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

  2011cited by this paper
• Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.

  2011cited by this paper
• A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia.

  2010cited by this paper
• Effect of medication-related factors on adherence in people with schizophrenia: A European multi-centre study

  2010cited by this paper
• A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

  2010cited by this paper
• Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years

  2010cited by this paper
• Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

  2010cited by this paper
• Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

  2010cited by this paper
• How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?

  2010cited by this paper
• Relative vs. absolute measures of benefit and risk: what’s the difference?

  2010cited by this paper
• Comparative Effectiveness of Long-Acting Risperidone in New Zealand

  2010cited by this paper
• A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

  2010cited by this paper
• Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  2010cited by this paper
• Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.

  2010cited by this paper
• Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

  2010cited by this paper
• Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

  2010cited by this paper
• Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

  2010cited by this paper
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• The experiences of carers in Taiwanese culture who have long-term schizophrenia in their families: a phenomenological study.

  2009cited by this paper
• Depot and oral antipsychotics: patient preferences and attitudes are not the same thing

  2009cited by this paper
• Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System

  2009cited by this paper
• Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.

  2009cited by this paper
• P.3.c.068 Efficacy outcomes of risperidone long acting injection in patients previously on oral atypicals versus conventional depots

  2009cited by this paper
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

  2008cited by this paper
• THE USE OF FLUPHENAZINE DECANOATE ( MODECATE ) DEPOT THERAPY IN OUTPATIENT SCHIZOPHRENICS-A RETROSPECTIVE STUDY

  2008cited by this paper
• Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors.

  2008cited by this paper
• The attitude of patients towards antipsychotic depot treatment

  2007cited by this paper
• A person-centered workplace: the foundation for person-centered caregiving in long-term care.

  2007cited by this paper
• Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.

  2007cited by this paper
• Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.

  2007cited by this paper
• Relationships among subjective and objective measures of adherence to oral antipsychotic medications.

  2007cited by this paper
• Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

  2007cited by this paper
• Long-Acting Injectable Risperidone Compared with Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity

  2006cited by this paper
• Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence

  2006cited by this paper
• Health resource utilization associated with switching to risperidone long‐acting injection

  2006cited by this paper
• Attitudes of psychiatrists toward antipsychotic depot medication.

  2006cited by this paper
• Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

  2006cited by this paper
• Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.

  2006cited by this paper
• Defining and assessing adherence to oral antipsychotics: a review of the literature.

  2005cited by this paper
• Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.

  2005cited by this paper
• Antipsychotic depot medication and attitudes of community psychiatric nurses.

  2005cited by this paper
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders

  2005cited by this paper
• PMH23 IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON HOSPITALIZATION AND MEDICATION USE IN PATIENTS WITH SCHIZOPHRENIA

  2005cited by this paper
• Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

  2005cited by this paper

• Clinical effectiveness of long-acting injectable antipsychotics in schizophrenia spectrum disorders: real-world mirror-image evidence

  2026cites this paper
• Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data

  2026cites this paper
• Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview

  2026cites this paper
• Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

  2026cites this paper
• Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States.

  2026cites this paper
• Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey Study

  2025cites this paper
• Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia

  2025cites this paper
• Forty years of research trends in long-acting injectable antipsychotics: A bibliometric analysis

  2025cites this paper
• Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report.

  2025cites this paper
• Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia

  2025cites this paper
• Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia

  2025cites this paper
• Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia

  2025cites this paper
• Surgical Vs Traditional Schizophrenia Treatment: What Research Shows

  2025cites this paper
• Long‐Acting Injectable Antipsychotic Use and Discontinuation Rates in Children and Adolescents With Schizophrenia Using Medicaid Claims Data

  2025cites this paper
• Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation?

  2025cites this paper
• The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment

  2025cites this paper
• Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study

  2025cites this paper
• Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes

  2025cites this paper
• Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial

  2025cites this paper
• Aripiprazole Long-acting Injectable Two-injection Start to Manage Supersensitivity Psychosis: A Case Report

  2025cites this paper
• Identifying longitudinal medication adherence patterns of antipsychotic treatments: A real‐world cohort study in Catalonia, Spain

  2025cites this paper
• Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review

  2025cites this paper
• Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study

  2025influential citation
• Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotic Agents for the Treatment of Patients With Schizophrenia: Results From the US DECIDE Survey

  2025cites this paper
• Long-term efficacy and safety of paliperidone palmitate monthly injection and oral paliperidone extended-release tablets in schizophrenia, a randomized controlled trial.

  2025cites this paper
• Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia

  2025cites this paper
• Reducing burst release and enhancing sustained release in SAIB-based implants: The role of polyphenol-modification.

  2025cites this paper
• Treatment effectiveness and preference in patients with schizophrenia switched from oral standard of care atypical antipsychotics to aripiprazole once-monthly: a brief report over a six-month period

  2025cites this paper
• Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)

  2025cites this paper
• Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• From the Editor-in-Chief’s Desk: Long-Acting Injectable Antipsychotics

  2025cites this paper
• Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study

  2025cites this paper
• The place of risperidone in situ microparticles (ISM®) among long-acting injectable antipsychotics in schizophrenia treatment

  2025cites this paper
• Long-acting injectable antipsychotics for patients with first-episode and early-phase schizophrenia: still not considered often enough

  2025cites this paper
• Attitudes of Italian psychiatrists towards the use of Long-Acting Injectable antipsychotics in the management of schizophrenia relapse: insights from the ALIA study.

  2025cites this paper
• Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: a mirror-image study

  2025cites this paper
• Extended-Release Buprenorphine Could Overcome Barriers to Medical Treatment of Opioid Use Disorder in At-Risk Populations.

  2025cites this paper
• Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic–Based Strategies

  2025cites this paper
• Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia

  2025influential citation
• Exploring Patient, Caregiver, and Prescriber Preferences for an Injectable Antipsychotic Administered Every 2 Months for the Maintenance Treatment of Schizophrenia: A Multicenter Qualitative Interview Study Conducted in Europe

  2025cites this paper
• From crisis to control: The role of long-acting injectable antipsychotics in reducing psychiatric service use in bipolar disorder.

  2025cites this paper
• Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs.

  2025cites this paper
• Optimising Aripiprazole Long-Acting Injectable: A Comparative Study of One- and Two-Injection Start Regimens in Schizophrenia with and Without Substance Use Disorders and Relationship to Early Serum Levels

  2025influential citation
• Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses

  2024cites this paper
• Effect of long-acting antipsychotic treatment on psychiatric hospitalization rate in early psychosis patients: a naturalistic study

  2024cites this paper
• Long-acting injectable antipsychotic care coordination in the medical hospital.

  2024cites this paper
• Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults

  2024cites this paper
• Complexity of patients with mental healthcare needs cared for by mental health clinical pharmacist practitioners in Veterans Affairs.

  2024cites this paper
• A recovery-oriented day hospital in psychiatry: A springboard for reintegration.

  2024cites this paper
• Catatonia-related adverse outcomes after long-acting injectable antipsychotics: Case series

  2024cites this paper
• Research Progress on the Clinical Effect and Economy of Risperidone in the Treatment of Schizophrenia

  2024cites this paper
• Focus on neurodevelopmental conditions and antipsychotics prescription patterns.

  2024cites this paper
• Symptomatic remission and recovery in major psychosis: Is there a role for BDNF? A secondary analysis of the LABSP cohort data.

  2024cites this paper
• Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes

  2024cites this paper
• Comparison of Psychiatric Readmission Rates for Child and Adolescent Patients on Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics: A Mirror Study

  2024cites this paper
• Systematic review of long-acting injectable antipsychotic medications approved from 2008 to october 2024 and agents in phase 3.

  2024cites this paper
• Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations

  2024cites this paper
• Comparing two transitioning strategies to paliperidone palmitate once-every-6-months

  2024cites this paper
• Dynamics of Clinical Manifestations and Social Functioning in Schizophrenia: A Non-interventional Observational Study of Paliperidone Palmitat Dosage Forms

  2024cites this paper
• Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis.

  2024cites this paper
• Guideline for pharmacological treatment of schizophrenia 2022

  2024cites this paper
• Health-Care Utilisation and Costs of Transition from Paliperidone Palmitate 1-Monthly to 3-Monthly Treatment for Schizophrenia: A Real-World, Retrospective, 24-Month Mirror-Image Study

  2024cites this paper
• Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care

  2024cites this paper
• Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia

  2024influential citation
• Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus

  2024cites this paper
• Extended lifetime expectancy in schizophrenia, role of measurement based care.

  2024cites this paper
• Mood disorders and somatic comorbidities.

  2024cites this paper
• A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial

  2024cites this paper
• Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia

  2024cites this paper
• Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy

  2024cites this paper
• Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis

  2024cites this paper
• Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults

  2024cites this paper
• In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan

  2024cites this paper
• The Use and Evaluation of Long-acting Injectable Antipsychotic Medications in Community-Dwelling Patients with Schizophrenia in Guangdong Province, China

  2024cites this paper
• Finding the Right Setting for the Right Treatment During the Acute Treatment of Individuals with Schizophrenia: A Narrative Review and Clinical Practice Guideline

  2024cites this paper
• Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review

  2024cites this paper
• Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States

  2023influential citation
• Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges

  2023cites this paper
• Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

  2023cites this paper
• The place of long-acting injectable antipsychotics in the treatment of schizophrenia

  2023cites this paper
• Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery

  2023influential citation
• Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis—A Retrospective Mirror-Image Study

  2023cites this paper
• The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data

  2023cites this paper
• Utilization of psychotropic medicines in Romania during 1998–2018

  2023cites this paper
• BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

  2023cites this paper
• The impact of the COVID-19 pandemic on the trend of prescribing long-acting injections of paliperidone and risperidone in Central Serbia

  2023cites this paper
• Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation

  2023cites this paper
• Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery

  2023cites this paper
• Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly

  2023cites this paper
• Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.

  2023cites this paper
• Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.

  2023cites this paper
• Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study

  2023cites this paper
• Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic

  2023cites this paper
• Comparative Safety of Long-Acting Injectable Antipsychotics: A Systematic Review and Network Meta-Analysis

  2023influential citation
• Sociodemographic and clinical factors associated with prescription of first- versus second-generation long-acting antipsychotics in incarcerated adult males

  2023cites this paper
• High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders

  2023cites this paper
• Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety

  2023cites this paper
• A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior.

  2023cites this paper
• Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

  2023cites this paper
• Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting

  2023influential citation